EMA Committee Recommends Six New Medicines, Including Pancreatic Cancer Drug Daraxonrasib

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued positive opinions for six new medicines and five extensions of therapeutic indications. Notably, daraxonrasib (Rasonque) received a positive opinion for adults with metastatic pancreatic adenocarcinoma who have failed prior therapies. This recommendation is significant for treating a highly resistant tumor type, potentially offering a new option for patients with limited alternatives.